Roche Venture Fund — Full Portfolio

Entrada Therapeutics is a biotech company developing intracellular therapeutics based on its proprietary EEV Platform, aimed at reaching previously inaccessible or undruggable disease-causing targets inside cells.

BiotechHealthtechBoston, US

Nerissa Kreher(Executive Officer)inKory Wentworth(Executive Officer)inDipal Doshi(Chief Executive Officer)inNathan Dowden(Executive Officer)inNatarajan Sethuraman, PhD(President of Research and Development)Nathan J. Dowden(President and Chief Operating Officer)in

Co-investors5AM VenturesMPM BioImpactTCG CrossoverAgent Capital

Freenome develops early-stage cancer detection technology using blood tests to identify cancer in its earliest, most treatable phases.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesLondon

Riley Ennis(Co-Founder and Chief Product Officer)Charles Roberts(Director)inGabriel Otte(Director)in

BoardStuart Lawson(Director)

Co-investorsRA CapitalAME Cloud VenturesAndreessen HorowitzArtis VenturesAsset Management CompanyAverin Capital+8 more

COUR develops antigen-specific immunotherapies that reprogram the immune system to treat the underlying causes of autoimmune and immune-mediated diseases while preserving normal immune function.

BiotechHealthtech

Co-investorsAlpha Wave GlobalLumira VenturesAngelini VenturesJDRF T1D Fund

DiogenX is a preclinical-stage biotech company developing biologic therapeutics aimed at restoring insulin-producing beta cells for people with Type 1 diabetes.

BiotechDeep TechDigital HealthHealthtechMarseille, FR

Benjamin Charles(Co-Founder & CEO)Patrick Collombat(Co-Founder & Scientific Advisor)inJean-Pascal Tranié(Co-Founder)in

Co-investorsAdBio partnersBoehringer Ingelheim Venture FundSunstone CapitalJDRF T1D Fund

Komed Health provides a secure, real-time communication platform designed for hospitals to enhance collaboration among care teams and improve patient care delivery.

Digital HealthEnterprise SoftwareHealthtechSaaSZurich, CH

Marc(Technical Co-founder)

Co-investorsSICTIC

SpliceBio develops genetic medicines using a proprietary protein splicing platform to treat diseases caused by mutations in large genes.

BiotechDeep TechDigital HealthBarcelona, ES

Dr. Vila-Perelló(CEO)Dr. Frutos(Co-founder)

Co-investorsNovartis Venture FundSanofi VenturesYsios CapitalAsabys PartnersCriteria Bio VenturesNew Enterprise Associates (NEA)+2 more

Vivet Therapeutics is a clinical-stage biotechnology company developing recombinant adeno-associated virus (rAAV) gene therapies for rare, inherited metabolic diseases, including Wilson's Disease and cerebrotendinous xanthomatosis.

BiotechHealthtechParis, FR

Co-investorsHealthCapKurma PartnersNovartis Venture FundYsios CapitalColumbus Venture PartnersEurazeo+1 more

BiotechWatertown, US

Edward Mascioli(Executive Officer)Andrew Myers(Director)

BoardMarkus Goebel(Director)Henry Skinner(Director)Vikas Goyal(Director)Raj Parekh(Director)in

Board seatAnja Harmeier· per SEC Form D · $20M raise · filed Mar 2018

Co-investorsAdvent Life Sciences

Aligos is a clinical-stage biotechnology company developing therapeutics for liver and viral diseases, including chronic hepatitis B virus (HBV) infection and MASLD/MASH.

BiotechHealthtechSouth San Francisco, US

Leonid Beigelman(President)inLawrence M. Blatt(Chairman, President & CEO (Co-founder))inHardean Achneck(Executive Officer)inSushmita Chanda(Executive Vice President - Preclinical Development)inBrian Dowd(Executive Vice President - Controller)inLucinda Quan(Executive Vice President - General Counsel)in

Co-investorsMPM BioVentures 2014Vivo Capital

Portfolio company that completed a successful 2018 biotech IPO, resulting in a 9x return for RiverVest.

BiotechSan Carlos, US

Nenad Tomasevic(Executive Officer)Christopher Bebbington(Executive Officer, Director)Alejandro Dorenbaum(Executive Officer)

BoardFarah Champsi(Director)inJohn McKearn(Director)inPeter Moldt(Director)

Co-investorsAlta PartnersNew Enterprise Associates (NEA)RiverVest Venture PartnersSamsara BioCapital

Bonum Therapeutics develops antibody-controlled protein therapeutics that remain inactive until bound to their target, using a sensor-domain mechanism to deliver regulated, targeted activity.

BiotechHealthtechSeattle, US

John Mulligan(Executive Officer, Director, Promoter)inNeela Patel(Executive Officer)inDiane Hollenbaugh(Executive Officer)in

BoardSamuel Bjork(Director)inMonique Schiersing(Director)inJohn McKearn(Director)in

Co-investorsRiverVest Venture PartnersVivo Capital3x5 PartnersCodon CapitalDigitalis Ventures

Enthera Srl is a privately held pharmaceutical company founded in 2016 and based in Milan, Italy.

BiotechHealthtechMilan, IT

Co-investorsSofinnova PartnersIndaco Venture PartnersAbbVieJDRF T1D Fund

Epibiologics develops protein degradation medicines using protein sciences and antibody engineering capabilities.

BiotechMedical DevicesSan Mateo, US

Ann Lee-Karlon(Executive Officer, Director)Mitchell Mutz(Executive Officer, Director)James Wells(Director)

BoardSamuel Bjork(Director)Alexandra Cantley(Director)Seiji Miyahara(Director)

Co-investorsAvego BioScience CapitalGV (Google Ventures)Mission BiocapitalNovartis Venture FundSamsara BioCapitalTaiho Ventures, LLC+3 more

Forcefield Therapeutics develops cardioprotective proteins for the treatment of cardiac disease, with an initial focus on myocardial infarction (heart attack).

BiotechHealthtechMedical Devices

John

GlycoEra develops glycan-based therapeutics, applying glycoengineering technology to create biologic drugs.

BiotechHealthtechNewton, US

Ganesh V. Kaundinya(President & CEO)in

Co-investors5AM VenturesCatalio Capital Management, LPLifeArc VenturesSixty Degree CapitalSofinnova PartnersAgent Capital+1 more

Portfolio company acquired by Roche.

BiotechSeattle, US

John Mulligan(Executive Officer, Director, Promoter)Mitchell Mutz(Director)Nicholas Walrod(Director)

BoardJohn McKearn(Director)inKarl Handelsman(Director)

Co-investorsDigitalis VenturesRiverVest Venture Partners

The National Kidney Foundation works to eliminate preventable kidney disease, accelerate innovation in patient care, and address structural inequities in kidney treatment and transplantation services.

HealthtechImpact & Social Good

Co-investorsYsios CapitalBioGeneration VenturesEpidarex CapitalScottish National Investment BankSofinnova Partners

Kumquat Biosciences is a biotech company developing small-molecule cancer therapeutics, combining drug discovery and clinical expertise to advance new oncology treatments.

BiotechSan Diego, US

Yi Liu(Executive Officer, Director)inLynn Yang(Director)

BoardCarl Gordon(Director)in

Co-investorsEcoR1 CapitalOrbiMed

Minoryx is a registration-stage biotech company developing novel therapies for severe, orphan genetic diseases of the central nervous system, with a lead compound (leriglitazone) in clinical trials for conditions including cerebral adrenoleukodystrophy, Friedreich's Ataxia, and Rett syndrome.

BiotechDeep TechHealthtechMedical DevicesMataró, ES

Marc Martinell(Co-Founder & Chief Executive Officer)

Co-investorsChiesi VenturesCriteria Bio VenturesFund+Invivo Capital PartnersKurma PartnersYsios Capital+1 more

Mironid is a drug development company building a pipeline of therapies targeting cAMP-degrading phosphodiesterase enzymes to treat Autosomal Dominant Polycystic Kidney Disease (ADPKD) and other rare kidney diseases.

BiotechMedical Devices

Adele Rowley(Chief Scientific Officer)

Co-investorsEpidarex CapitalSofinnova PartnersBioGeneration VenturesScottish National Investment Bank

Mission Therapeutics develops therapeutics targeting deubiquitylating enzymes (DUBs), such as USP30, which regulate ubiquitylation and processes including mitophagy and protein homeostasis.

BiotechHealthtech

Co-investorsPfizer Venture InvestmentsSofinnova PartnersSR One Capital Management

NMD Pharma is a clinical-stage biotech company developing first-in-class small-molecule therapies that selectively target skeletal muscle to treat rare neuromuscular diseases and age-related conditions.

BiotechDeep TechHealthtechMedical DevicesAarhus, DK

Co-investorsJeito CapitalNovo HoldingsInkef

Noema Pharma develops a late-stage portfolio of oral small molecule therapeutics for people with neurological and related disorders, targeting both orphan and larger indications with significant unmet medical needs.

BiotechHealthtechMedical Devices

Ilise Lombardo(Chief Executive Officer)inVolker Knappertz(Executive Vice President of Research & Development)inMichael Samar(Chief Financial Officer)inRob Lasser(Chief Medical Officer)in

Co-investorsBioMedPartnersJeito CapitalSofinnova PartnersEQTEQT Life SciencesForbion+2 more

BiotechPleasanton, US

Bill W. Colston, Ph.D.(Director)Klint Rose, Ph.D.(Chief Scientific Officer)Juan G. Santiago(Executive Officer, Director, Promoter)Klint Rose(Executive Officer, Director, Promoter)Amy Hiddessen(Executive Officer, Director, Promoter)Barney E. Saunders,Ph.D.(Chief Executive Officer)

Co-investors5AM VenturesCota Capital

Sarepta develops precision genetic medicines for people with rare diseases, with a focus on rare neuromuscular conditions.

BiotechHealthtechCambridge, US

WILLIAM CIAMBRONE(Executive Officer)DOUGLAS S. INGRAM(Executive Officer, Director)inDAVID TYRONNE HOWTON(Executive Officer)SANDESH MAHATME(Executive Officer)GILMORE O'NEILL(Executive Officer)ALEXANDER CUMBO(Executive Officer)

Co-investorsAvoro Capital Advisors

Tempest Therapeutics is a clinical-stage biotechnology company developing in vivo CAR-T cell therapies for autoimmune and oncology indications.

BiotechHealthtechBrisbane, US

Stephen Brady(Director)Matthew Angel(Executive Officer, Director)Nicholas Maestas(Executive Officer)Thomas Woiwode(Director)Geoffrey Nichol(Director)Thomas W. Dubensky(Executive Officer, Director)

Co-investorsF-Prime CapitalLAVLilly Asia VenturesNew Enterprise Associates (NEA)Quan Capital